The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology Working Group on peripheral circulation: Endorsed by the Association for Research into Arterial Structure and Physiology (ARTERY) Society

Charalambos Vlachopoulos, Panagiotis Xaplanteris, Victor Aboyans, Marianne Brodmann, Renata Cífková, Francesco Cosentino, Marco De Carlo, Augusto Gallino, Ulf Landmesser, Stéphane Laurent, John Lekakis, Dimitri P Mikhailidis, Katerina K Naka, Athanasios D Protogerou, Damiano Rizzoni, Arno Schmidt-Trucksäss, Luc Van Bortel, Thomas Weber, Akira Yamashina, Reuven ZimlichmanPierre Boutouyrie, John Cockcroft, Michael O'Rourke, Jeong Bae Park, Giuseppe Schillaci, Henrik Sillesen, Raymond R Townsend

    589 Citationer (Scopus)

    Abstract

    While risk scores are invaluable tools for adapted preventive strategies, a significant gap exists between predicted and actual event rates. Additional tools to further stratify the risk of patients at an individual level are biomarkers. A surrogate endpoint is a biomarker that is intended as a substitute for a clinical endpoint. In order to be considered as a surrogate endpoint of cardiovascular events, a biomarker should satisfy several criteria, such as proof of concept, prospective validation, incremental value, clinical utility, clinical outcomes, cost-effectiveness, ease of use, methodological consensus, and reference values. We scrutinized the role of peripheral (i.e. not related to coronary circulation) noninvasive vascular biomarkers for primary and secondary cardiovascular disease prevention. Most of the biomarkers examined fit within the concept of early vascular aging. Biomarkers that fulfill most of the criteria and, therefore, are close to being considered a clinical surrogate endpoint are carotid ultrasonography, ankle-brachial index and carotid-femoral pulse wave velocity; biomarkers that fulfill some, but not all of the criteria are brachial ankle pulse wave velocity, central haemodynamics/wave reflections and C-reactive protein; biomarkers that do no not at present fulfill essential criteria are flow-mediated dilation, endothelial peripheral arterial tonometry, oxidized LDL and dysfunctional HDL. Nevertheless, it is still unclear whether a specific vascular biomarker is overly superior. A prospective study in which all vascular biomarkers are measured is still lacking. In selected cases, the combined assessment of more than one biomarker may be required.

    OriginalsprogEngelsk
    TidsskriftAtherosclerosis
    Vol/bind241
    Udgave nummer2
    Sider (fra-til)507-32
    Antal sider26
    ISSN0021-9150
    DOI
    StatusUdgivet - aug. 2015

    Fingeraftryk

    Dyk ned i forskningsemnerne om 'The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology Working Group on peripheral circulation: Endorsed by the Association for Research into Arterial Structure and Physiology (ARTERY) Society'. Sammen danner de et unikt fingeraftryk.

    Citationsformater